GlassScriptPhysician profile
Michael A Wiedemann
NPI 1306898002
$1,076.71
in general payments reported to CMS, 2019-2025
19 companies · $69.31 in 2025
The $69.31 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $130 · 2021: $207 · 2022: $233 · 2023: $199 · 2024: $121 · 2025: $69.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biom'Up France Sas | $179.12 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $166.36 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $145.00 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Pfizer INC. | $91.61 | 2019-2024 | |
| Boston Scientific Corporation | $60.46 | 2022 | |
| Astellas Pharma US INC | $55.49 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $53.45 | 2019-2025 | Paragard T 380a |
| Coloplast Corp | $43.80 | 2019 | |
| Mylan Pharmaceuticals INC. | $41.21 | 2022 | |
| Merck Sharp & Dohme LLC | $40.63 | 2022-2023 | Gardasil 9 |
| Organon LLC | $39.05 | 2023-2025 | Nexplanon, Jada System |
| Genentech USA, INC. | $34.70 | 2024 | Vabysmo |
| Evofem Biosciences, INC. | $32.54 | 2021-2022 | |
| Hologic Sales and Service, LLC | $24.17 | 2020 | |
| Myovant Sciences INC. | $15.99 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $14.43 | 2024 | |
| Millicent US INC | $13.41 | 2020 | |
| Therapeuticsmd, INC. | $13.26 | 2020 | |
| Lupin INC. | $12.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wiedemann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.